A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial

Bibliographic Details
Main Authors: Schouten, Philip C., Dackus, Gwen M. H. E., Marchetti, Serena, van Tinteren, Harm, Sonke, Gabe S., Schellens, Jan H. M., Linn, Sabine C.
Format: Online
Language:English
Published: BioMed Central 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915081/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915081/

Similar Items